Myriad amends Flurizan Phase III protocol

MYGN said FDA approved an amended protocol for an ongoing U.S. Phase III trial of Flurizan (MPC-7869) to treat Alzheimer's disease (AD). Changes in the protocol include increasing enrollment to 1,600 ...